Barclays
VIVO

Barclays’s Meridian Bioscience Inc VIVO Stock Holding History

Barclays’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,293
Closed -$1.67M – 5547
2022
Q4 		$1.67M Buy
50,293
+20,319
+68% +$654K ﹤0.01% 2382
2022
Q3 		$945K Buy
29,974
+16,434
+121% +$532K ﹤0.01% 2285
2022
Q2 		$412K Sell
13,540
-33,391
-71% -$903K ﹤0.01% 3011
2022
Q1 		$1.22M Sell
46,931
-17,201
-27% -$409K ﹤0.01% 2247
2021
Q4 		$1.31M Buy
64,132
+21,545
+51% +$413K ﹤0.01% 2653
2021
Q3 		$818K Buy
42,587
+9,833
+30% +$196K ﹤0.01% 2901
2021
Q2 		$727K Sell
32,754
-28,183
-46% -$598K ﹤0.01% 2858
2021
Q1 		$1.6M Buy
60,937
+1,370
+2% +$32.6K ﹤0.01% 2471
2020
Q4 		$1.11M Sell
59,567
-5,495
-8% -$103K ﹤0.01% 2681
2020
Q3 		$1.1M Buy
65,062
+21,888
+51% +$425K ﹤0.01% 2608
2020
Q2 		$1.01M Sell
43,174
-9,894
-19% -$143K ﹤0.01% 2751
2020
Q1 		$444K Sell
53,068
-19,969
-27% -$168K ﹤0.01% 3685
2019
Q4 		$713K Buy
73,037
+16,528
+29% +$155K ﹤0.01% 3975
2019
Q3 		$537K Sell
56,509
-4,631
-8% -$48.8K ﹤0.01% 4192
2019
Q2 		$726K Buy
61,140
+27,402
+81% +$330K ﹤0.01% 4002
2019
Q1 		$594K Buy
33,738
+17,742
+111% +$295K ﹤0.01% 3950
2018
Q4 		$278K Sell
15,996
-34,863
-69% -$595K ﹤0.01% 4346
2018
Q3 		$757K Buy
50,859
+21,973
+76% +$341K ﹤0.01% 3899
2018
Q2 		$460K Sell
28,886
-1,606
-5% -$24K ﹤0.01% 4029
2018
Q1 		$432K Buy
30,492
+8,004
+36% +$118K ﹤0.01% 4120
2017
Q4 		$315K Buy
22,488
+16,872
+300% +$247K ﹤0.01% 4292
2017
Q3 		$81K Sell
5,616
-5,009
-47% -$71.6K ﹤0.01% 5071
2017
Q2 		$167K Buy
10,625
+9,102
+598% +$131K ﹤0.01% 4520
2017
Q1 		$21K Sell
1,523
-1,201
-44% -$16.8K ﹤0.01% 5793
2016
Q4 		$48K Sell
2,724
-1,314
-33% -$23.1K ﹤0.01% 5195
2016
Q3 		$78K Buy
4,038
+3,649
+938% +$71.4K ﹤0.01% 4676
2016
Q2 		$8K Buy
+389
New +$7.63K ﹤0.01% 5626
2015
Q4 		– Sell
-14,828
Closed -$284K – 6752
2015
Q3 		$252K Sell
14,828
-32,602
-69% -$596K ﹤0.01% 3971
2015
Q2 		$853K Buy
47,430
+46,182
+3,700% +$856K ﹤0.01% 3017
2015
Q1 		$24K Sell
1,248
-3,693
-75% -$68.3K ﹤0.01% 5739
2014
Q4 		$79K Sell
4,941
-2,730
-36% -$46.8K ﹤0.01% 5380
2014
Q3 		$130K Buy
7,671
+6,789
+770% +$133K ﹤0.01% 5120
2014
Q2 		$17K Sell
882
-1,318
-60% -$27.1K ﹤0.01% 6595
2014
Q1 		$46K Buy
2,200
+208
+10% +$4.77K ﹤0.01% 6072
2013
Q4 		$52K Sell
1,992
-18,874
-90% -$464K ﹤0.01% 6163
2013
Q3 		$480K Sell
20,866
-10,205
-33% -$238K ﹤0.01% 4163
2013
Q2 		$668K Buy
+31,071
New +$670K ﹤0.01% 3880

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's VIVO Position: Q1 2023 in Review

Barclays sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 50,293 shares — an estimated $1.67M sold.

Barclays first reported a position in VIVO in Q2 2013 and held it in 37 quarters. The position peaked at $1.67M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Barclays reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 50,293 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.67M.
  • Barclays first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 37 quarters.
  • Barclays's Meridian Bioscience Inc position peaked at $1.67M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.